相似文献
1
Integrins in cancer: biological implications and therapeutic opportunities.
Nat Rev Cancer. 2010 Jan;10(1):9-22. doi: 10.1038/nrc2748.
2
Small molecule integrin antagonists in cancer therapy.
Mini Rev Med Chem. 2009 Oct;9(12):1439-46. doi: 10.2174/138955709789957404.
3
Targeting integrins in malignant glioma.
Target Oncol. 2010 Sep;5(3):175-81. doi: 10.1007/s11523-010-0156-3. Epub 2010 Sep 4.
4
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Anticancer Res. 2012 Oct;32(10):4213-23.
5
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Expert Opin Investig Drugs. 2008 Aug;17(8):1225-35. doi: 10.1517/13543784.17.8.1225.
6
The role of integrins in glioma biology and anti-glioma therapies.
Curr Pharm Des. 2011;17(23):2402-10. doi: 10.2174/138161211797249189.
7
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Clin Genitourin Cancer. 2006 Mar;4(4):299-302. doi: 10.3816/CGC.2006.n.012.
8
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
Eur J Cancer. 2003 May;39(7):917-26. doi: 10.1016/s0959-8049(03)00057-1.
9
Cilengitide treatment for malignant glioma: current status and future direction.
Neurol Med Chir (Tokyo). 2012;52(8):539-47. doi: 10.2176/nmc.52.539.
10
Integrins: molecular targets in cancer therapy.
Curr Oncol Rep. 2006 Mar;8(2):96-103. doi: 10.1007/s11912-006-0043-3.
引用本文的文献
1
Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer Ga-pentixafor-c(RGDfK) for PET-CT imaging.
Eur J Nucl Med Mol Imaging. 2025 Sep 9. doi: 10.1007/s00259-025-07549-9.
2
Role and mechanism of Integrin α5β1 in bone formation and disease.
Front Cell Dev Biol. 2025 Aug 14;13:1632710. doi: 10.3389/fcell.2025.1632710. eCollection 2025.
3
Comprehensive exome profiling identifies mutation as a driver in gastric cancer with ovarian metastasis.
Theranostics. 2025 Jul 24;15(16):8202-8221. doi: 10.7150/thno.113382. eCollection 2025.
4
Amino Acid Transporters in Glioblastoma: Implications for Diagnosis, Disease Monitoring, Therapeutic Targeting, and Drug Delivery.
Mol Diagn Ther. 2025 Aug 22. doi: 10.1007/s40291-025-00810-9.
5
NK-Cell-Derived Extracellular Vesicles Engineered to Carry Senolytics Eliminate Chemotherapy-Induced Senescent Osteosarcoma Cells.
J Extracell Vesicles. 2025 Jul;14(7):e70123. doi: 10.1002/jev2.70123.
6
The role of exosomes in bladder cancer immunotherapy.
J Natl Cancer Cent. 2025 May 2;5(3):252-266. doi: 10.1016/j.jncc.2025.04.001. eCollection 2025 Jun.
7
HIF-1 promotes murine breast cancer brain metastasis by increasing production of integrin β3-containing extracellular vesicles.
J Clin Invest. 2025 Jul 15;135(14). doi: 10.1172/JCI190470.
8
Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.
MedComm (2020). 2025 Jul 11;6(7):e70292. doi: 10.1002/mco2.70292. eCollection 2025 Jul.
9
Tissue-seeking dyes for in vivo applications.
Smart Mol. 2024 Oct 24;2(4):e20240029. doi: 10.1002/smo.20240029. eCollection 2024 Dec.
10
Fibulin-7 and its bioactive fragments: emerging immunomodulatory roles in disease.
Inflamm Res. 2025 Jul 7;74(1):101. doi: 10.1007/s00011-025-02067-8.
本文引用的文献
1
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.
2
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.
Nat Med. 2009 Oct;15(10):1163-9. doi: 10.1038/nm.2009. Epub 2009 Sep 6.
3
Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo.
Mol Ther. 2009 Jun;17(6):1012-21. doi: 10.1038/mt.2009.39. Epub 2009 Mar 10.
4
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell. 2009 Mar 3;15(3):232-9. doi: 10.1016/j.ccr.2009.01.021.
5
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.
6
Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis.
Cancer Res. 2009 Feb 15;69(4):1469-76. doi: 10.1158/0008-5472.CAN-08-2678. Epub 2009 Feb 10.
7
Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis.
Cancer Res. 2009 Feb 15;69(4):1383-91. doi: 10.1158/0008-5472.CAN-08-3612. Epub 2009 Feb 10.
8
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
J Clin Invest. 2009 Feb;119(2):252-66. doi: 10.1172/JCI37160. Epub 2009 Jan 19.
9
Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
Cancer Res. 2009 Jan 15;69(2):475-82. doi: 10.1158/0008-5472.CAN-08-2649.
10
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Cancer Res. 2009 Jan 15;69(2):466-74. doi: 10.1158/0008-5472.CAN-08-3078.
Zotero 插件